All
Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.
Illuminating Compassion in Cancer Care
The journey that led to the creation of the Extraordinary Healer Award for Oncology Nursing began with a simple, yet profound, observation.
Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program
Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients.
Reassessing Immunotherapy Use in Advanced Renal Cell Carcinoma
There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting.
Recognizing Symptoms During Head and Neck Cancer Awareness Month
Dr. Zafar Sayed discuss the importance of recognizing Head and Neck Cancer Awareness Month and highlights early symptoms of the disease to be aware of.
AI Tool May Better Predict Transplant Risk in Myelofibrosis
An AI model may help identify patients with myelofibrosis at high risk of early death after transplant, according to an expert.
Daffodils and Determination from a Patient with Chronic Lymphocytic Leukemia
Each spring, I find strength and hope in the daffodils I grow, helping me face chronic lymphocytic leukemia with renewed determination.
First Patient Dosed in a Phase 1/2 Trial for Small Cell Lung Cancer
The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors.
First Patient with Colon Cancer Dosed in a Phase 2 Study of TCMCB07
The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal cancer undergoing chemotherapy.
Radiation Delay in NSCLC May Aid Outcomes, But Raises Toxicity Risks
Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.
Radiation Therapy Now More Targeted and Tolerable in GI Cancer
Radiation therapy for gastrointestinal cancers is more precise and easier to tolerate due newer technologies and personalized care, according to experts.
Dr. Grivas Highlights Three Practice-Changing Trials in Bladder Cancer
Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three practice-changing phase 3 trials.
Antibody-Drug Conjugates Changed the Standard of Care in Bladder Cancer
Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, replacing single-agent treatments.
New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment
Experts at Hackensack Meridian Jersey Shore University Medical Center have successfully treated their first patients using the TAMP™ therapy platform.
How I Manage When My Social Media Friends with Cancer Disappear
I stay in the cancer social media world because it helps me cope, even when friends disappear and I’m left wondering if they’re resting, retreating or gone.
U.S. Centers Seek Namodenoson for Pancreatic Cancer Compassionate Use
U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for patients with pancreatic cancer.
Emactuzumab Gets Fast Track Designation in Tenosynovial Giant Cell Tumors
Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who would not benefit from surgery.
Raising Awareness on Multidisciplinary Approaches in GI Cancers
Patients with gastrointestinal cancer may benefit from multidisciplinary care and open communication with their care team, as per an expert.
FDA sBLA Submitted for Anktiva Plus BCG in Papillary Bladder Cancer
A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.
TLX101 Demonstrated Efficacy in Recurrent High-Grade Glioma
TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from the phase 2 IPAX-Linz study.
15% of U.S. Cancer Patients Are Active Smokers at Time of Diagnosis
The addition of smoking status to the National Cancer Database might inform more effective treatment for smokers with cancer.
Sometimes, Distractions Help During Breast Cancer
After a mammogram and breast cancer scare, a Broadway show provided a welcome distraction and joy, reminding me of life's beauty.
Bria-IMT Combo Outperforms Other Metastatic Breast Cancer Treatments
Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ metastatic breast cancer.
Bexmarilimab Plus Vidaza Elicit Responses in Myelodysplastic Syndromes
Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome.
Understanding Esophageal Cancer: Early Signs, Risks and Key Insights
Dr. Nataliya Uboha sat down to discuss the early warning signs of esophageal cancer, as well as important key takeaways for those with the disease.
Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC
Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma.
Spring Looks Different This Year
What is lovely never dies, but passes into other loveliness, Stardust or seafoam, flower or winged air. ― Thomas Bailey Aldrich
First Patient Treated in Trial of PHST001 for Advanced Solid Tumors
Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.
Clinical Trial of NEO100 Recruiting Patients With Malignant Gliomas
A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.
